氯氮平治疗患者流涎与血药浓度升高的关联
本研究基于大型治疗药物监测数据库,比较有流涎(n=72)与无相关不良反应(n=323)的氯氮平治疗患者的药代动力学参数。流涎组氯氮平血浆浓度及浓度-剂量比均显著更高(p<0.001),协变量分析后差异仍存在,提示治疗药物监测可能有助于预防或管理氯氮平相关流涎。
要点
- 流涎患者氯氮平血浆浓度及浓度-剂量比显著高于无流涎者。
- 协变量分析后浓度差异仍显著,吸烟与非吸烟亚组结果相似。
- 治疗药物监测可能有助于预防或管理氯氮平相关流涎。
核心结论
- 流涎患者氯氮平血浆浓度及浓度-剂量比升高,提示治疗药物监测可能用于预防或管理流涎。
研究设计与样本
- 基于大型氯氮平治疗药物监测数据库的回顾性比较研究,流涎组72例,无相关不良反应对照组323例。
主要发现
- 流涎组氯氮平血浆浓度和浓度-剂量比均高于对照组(Mann-Whitney U检验p<0.001)。
- 两组人口学特征无差异,但流涎组日剂量更高(p=0.005)且吸烟者比例更低(p=0.028)。
- 协变量分析后血浆浓度和浓度-剂量比差异仍显著(p<0.001),吸烟与非吸烟亚组分析结果相似。
临床怎么用
- 对出现流涎的氯氮平治疗患者,可考虑监测氯氮平血浆浓度以辅助评估和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Hypersalivation is a common, clozapine-related adverse drug reaction with a serious impact on quality of life. Pharmacokinetic correlates of clozapine-related hypersalivation have evaded attention. The purpose of this study was to compare pharmacokinetic parameters between clozapine-treated patients with vs. without hypersalivation from a large therapeutic drug monitoring database. METHODS: Out of a large therapeutic drug monitoring dataset of clozapine-treated patients, we compared a group of patients with hypersalivation (n = 72) and a control group of patients without any adverse reactions in this regard (n = 323). Comparisons included plasma concentrations and concentrations-by-dose as well as demographic characteristics between groups. Post-hoc analyses were performed separately in smokers and non-smokers. We used the non-parametric Mann-Whitney U test and the chi-square test, while effects of confounders were assessed using a bootstrapping analysis of covariance. RESULTS: Patients with hypersalivation had higher clozapine plasma concentrations and concentrations-by-dose (p < 0.001 for the Mann-Whitney U test in both cases). Groups did not differ regarding demographic characteristics except for clozapine daily dose and percentage of smokers (p = 0.005 for the Mann-Whitney U test and p = 0.028 for the chi-square test, respectively). There were fewer smokers across patients with hypersalivation compared with patients without and daily doses were higher in patients with hypersalivation. After analysis of covariance, differences remained for both plasma concentrations and concentrations-by-dose (p < 0.001 for both). Post hoc analyses in smokers and non-smokers separately reported similar findings. CONCLUSIONS: Elevated clozapine plasma concentrations and higher concentrations-by-dose were observed in patients with hypersalivation. A potential role for therapeutic drug monitoring in the prevention or management of clozapine-related hypersalivation is suggested.
引用
- Schoretsanitis G, Kuzin M, Kane JM, et al. Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation. Clin Pharmacokinet. 2020. PMID: 33000411. doi:10.1007/s40262-020-00944-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。